Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Rapid Readouts: Results from the Phase 3 CHRONOS-3 Trial for Relapsed iNHL

May 7th 2021

Tycel J. Phillips, MD, presents slides from the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021 of results from the phase 3 CHRONOS-3 study of copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Dr. Alkharabsheh on Future Research Directions in MPNs

May 5th 2021

Omar Alkharabsheh, MD, discusses future research directions for the treatment of patients with myeloproliferative neoplasms.

Emerging Combinations for FLT3-Mutated AML

May 5th 2021

Jessica K. Altman, MD, and Naval G. Daver, MD, review novel combinations under investigation for the treatment of FLT3-mutated acute myeloid leukemia.

BCL2 Inhibitor Combinations in FLT3-Mutated AML

May 5th 2021

A discussion on the use of venetoclax combinations with FLT3 inhibitors, especially in older patients with FLT3-mutated acute myeloid leukemia.

Dr. Grunwald on the Established and Potential Utility of Tisagenlecleucel in ALL

May 5th 2021

Michael R. Grunwald, MD, FACP, discusses the established and potential utility of tisagenlecleucel in patients with acute lymphoblastic leukemia.

Dr. Grunwald on Preventing Relapse in Lymphoid and Myeloid Malignancies

May 4th 2021

Michael R. Grunwald, MD, FACP, discusses preventing relapse in patients with lymphoid and myeloid malignancies following allogeneic transplantation.

Dr. Ansell on Challenges With PET Scans in Hodgkin Lymphoma

May 4th 2021

Stephen M. Ansell, MD, PhD, discusses challenges with positron emission tomography scans in patients with Hodgkin lymphoma.

Unmet Needs in GVHD

May 4th 2021

Challenges and unmet needs in steroid-refractory GVHD and advice to community oncologists for the optimal management of disease.

Safety and Efficacy of PI3K Inhibitors in MZL and FL

May 4th 2021

Expert hematologist-oncologists share insights about the role of PI3K inhibition and immunosuppression in indolent non-Hodgkin lymphoma and review the safety and efficacy of idelalisib, duvelisib, and copanlisib.

Second-Line Chemoimmunotherapy for MZL and FL

May 4th 2021

Anthony Mato, MD, MSCE, and Lori A. Leslie, MD, consider treatment options for patients with relapsed/refractory disease after first-line chemoimmunotherapy.

Emerging Therapies for Acute and Chronic GVHD

May 4th 2021

Novel agents in the pipeline for the treatment of acute and chronic GVHD are discussed.

FDA Approval Insights: Liso-Cel in Refractory Large B-Cell Lymphoma

May 3rd 2021

Dr. Abramson discusses the significance of the FDA approval of lisocabtagene maraleucel in refractory large B-cell lymphoma and provided insight into the efficacy and safety profiles of the CAR T-cell therapy as reported in the TRANSCEND NHL 001 trial.

DPX-Survivac/Pembrolizumab Plus Cyclophosphamide to Be Examined in DLBCL

May 3rd 2021

Following feedback from the FDA, IMV Inc. and Merck have entered into an agreement to open a phase 2b clinical trial examining the combination of maveropepimut-S and pembrolizumab plus low-dose cyclophosphamide in patients with recurrent/refractory diffuse large B-cell lymphoma.

Sequential CD19-Directed CAR T-Cell Therapy and Allogeneic Transplant Provide Long-Term Responses in Pediatric B-ALL

April 30th 2021

Sequential therapy with CD19.28ζ-directed CAR T cells followed by allogeneic hematopoietic stem cell transplant induced durable disease control in a significant population of children and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Radich on the Impact of MRD on Survival Outcomes in AML

April 30th 2021

Jerald Radich, MD, discusses the impact of minimal residual disease on survival outcomes in patients with acute myeloid leukemia.

Narsoplimab Trial Results

April 29th 2021

The panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.

Narsoplimab: The Phase 2 Trial

April 29th 2021

Samer Khaled, MD reviews the design, results, and practical implications of the pivotal phase 2 trial of narsoplimab, a MASP-2 targeted monoclonal antibody under investigation for the treatment of thrombotic microangiopathy associated with hematopoietic stem cell transplantation.

Rapid Readouts: Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk MDS/CMML or LB AML

April 28th 2021

Joshua F. Zeidner, MD, presents data from the 62nd American Society of Hematology (ASH) Annual Meeting on an exploratory analysis of patient-reported outcomes from a randomized phase 2 trial of pevonedistat plus azacitidine vs azacitidine in higher-risk myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myeloid leukemia (AML).

New Approaches Seek to Meet the Challenge of Graft-Vs-Host Disease

April 28th 2021

The curative potential of allogeneic hematopoietic stem cell transplantation for many hematologic malignancies is hindered by the frequent development of graft-vs-host disease, a potentially fatal complication resulting from a complex interaction between donor immune cells in the graft and the host’s immune system.

Treatment Combinations in FLT3-Mutated AML

April 28th 2021

Experts in hematology comment on when it’s appropriate to use gilteritinib, particularly as a combination therapy, to treat patients with FLT3-mutated acute myeloid leukemia.